TY - JOUR
T1 - Neurologic Manifestations of Systemic Disease
T2 - Peripheral Nervous System
AU - Dworetz, Alex
AU - Graley, Christina
AU - Padia, Hiral
AU - Gwathmey, Kelly G.
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose of Review: The impact that systemic disease has on the peripheral nervous system is vast. Polyneuropathies due to these disorders fall into broad categories including metabolic diseases, nutritional deficiencies, rheumatological diseases, infectious diseases, and malignancy-associated disorders. This review focuses on the treatment of these systemic disease–associated polyneuropathies. Recent Findings: Many of the specific polyneuropathies covered in this review are relatively rare and understudied. As such treatment recommendations are based on expert opinion, small case series, and case reports. Even more prevalent polyneuropathies, such as diabetes-associated, will be covered, though these too often lack standard treatment approaches. The immune checkpoint inhibitor–associated polyneuropathies have garnered much attention recently. Current treatment recommendations for these polyneuropathies will be discussed. Summary: Recognition of polyneuropathies associated with the systemic disease is imperative as these acquired polyneuropathies represent potentially treatable disorders. In many circumstances, prompt identification and early treatment prevent permanent neurological deficits and pain. The reader is encouraged to consider these polyneuropathy etiologies in order to expedite diagnostic evaluation and if possible therapeutic intervention.
AB - Purpose of Review: The impact that systemic disease has on the peripheral nervous system is vast. Polyneuropathies due to these disorders fall into broad categories including metabolic diseases, nutritional deficiencies, rheumatological diseases, infectious diseases, and malignancy-associated disorders. This review focuses on the treatment of these systemic disease–associated polyneuropathies. Recent Findings: Many of the specific polyneuropathies covered in this review are relatively rare and understudied. As such treatment recommendations are based on expert opinion, small case series, and case reports. Even more prevalent polyneuropathies, such as diabetes-associated, will be covered, though these too often lack standard treatment approaches. The immune checkpoint inhibitor–associated polyneuropathies have garnered much attention recently. Current treatment recommendations for these polyneuropathies will be discussed. Summary: Recognition of polyneuropathies associated with the systemic disease is imperative as these acquired polyneuropathies represent potentially treatable disorders. In many circumstances, prompt identification and early treatment prevent permanent neurological deficits and pain. The reader is encouraged to consider these polyneuropathy etiologies in order to expedite diagnostic evaluation and if possible therapeutic intervention.
KW - diabetes
KW - Immune checkpoint inhibitor
KW - Nutritional deficiency
KW - Polyneuropathy
KW - Sarcoidosis
KW - Sjögren’s syndrome
UR - http://www.scopus.com/inward/record.url?scp=85089773732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089773732&partnerID=8YFLogxK
U2 - 10.1007/s11940-020-00631-7
DO - 10.1007/s11940-020-00631-7
M3 - Review article
AN - SCOPUS:85089773732
SN - 1092-8480
VL - 22
JO - Current Treatment Options in Neurology
JF - Current Treatment Options in Neurology
IS - 8
M1 - 25
ER -